Showing results (1-10 of 16) with videos related to
Sort By:
Pageof 2
British Journal of Clinical Pharmacology|December 3, 1999
Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferaseK Jorga, B Fotteler, P Heizmann, et al.British Journal of Clinical Pharmacology|December 22, 1999
Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studiesK Jorga, B Fotteler, L Banken, et al.Clinical Pharmacokinetics|August 19, 1999
Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patientsR Gieschke, B Fotteler, N Buss, et al.European Journal of Clinical Pharmacology|October 1, 1998
Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapyK M Jorga, B Fotteler, P Heizmann, et al.European Neurology|August 31, 2000
Effect of tolcapone on the haemodynamic effects and tolerability of desipramineK M Jorga, B Fotteler, M Modi, et al.Journal of Neurology|May 20, 1998
The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulationK Jorga, B Fotteler, G Sedek, et al.Journal of Clinical Pharmacology|May 12, 2000
Lack of interaction between tolcapone and tolbutamide in healthy volunteersK M Jorga, B Fotteler, R Gasser, et al.Clinical Pharmacology and Therapeutics|June 29, 2000
Population pharmacokinetics of levodopa in patients with Parkinson's disease treated with tolcaponeK Jorga, L Banken, B Fotteler, et al.Journal of Clinical Psychopharmacology|February 1, 1995
Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitorJ Dingemanse, J Kneer, B Fotteler, et al.European Neurology|January 1, 1997
The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulationsK Jorga, B Fotteler, M Schmitt, et al.Pageof 2